Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a research report issued on Sunday.

Separately, Cantor Fitzgerald restated a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN traded down $0.39 during trading on Friday, reaching $31.89. The company had a trading volume of 261,143 shares, compared to its average volume of 461,846. Supernus Pharmaceuticals has a twelve month low of $25.53 and a twelve month high of $40.28. The firm has a market capitalization of $1.78 billion, a PE ratio of 29.84 and a beta of 0.83. The firm's fifty day moving average is $36.02 and its 200 day moving average is $35.13.

Insider Activity

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares of the company's stock, valued at $307,444.95. The trade was a 10.56 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company's stock, valued at approximately $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,104 shares of company stock worth $440,263 over the last 90 days. 9.30% of the stock is owned by company insiders.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SUPN. Jefferies Financial Group Inc. bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth about $890,000. GF Fund Management CO. LTD. bought a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth $42,000. Ashford Capital Management Inc. increased its stake in shares of Supernus Pharmaceuticals by 0.3% in the fourth quarter. Ashford Capital Management Inc. now owns 545,775 shares of the specialty pharmaceutical company's stock valued at $19,735,000 after buying an additional 1,740 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Supernus Pharmaceuticals by 24.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 100,020 shares of the specialty pharmaceutical company's stock valued at $3,617,000 after buying an additional 19,824 shares during the last quarter. Finally, Woodline Partners LP lifted its position in Supernus Pharmaceuticals by 124.8% during the 4th quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock worth $15,326,000 after buying an additional 235,257 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.